INMED PHARMACEUTICALS INC. Operating Cash Flow
INMED PHARMACEUTICALS INC. (INM) reported Operating Cash Flow of -$8.64 million for the 12-month period ending 2026-06-30, per its S-4/A filed 2026-09-09.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-09-09
- INMED PHARMACEUTICALS INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$2.96M.
- INMED PHARMACEUTICALS INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$1.70M.
- INMED PHARMACEUTICALS INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$2.38M.
- INMED PHARMACEUTICALS INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$1.61M.
- INMED PHARMACEUTICALS INC. net cash provided by (used in) operating activities for fiscal 2023 was -$7.28M.
- INMED PHARMACEUTICALS INC. net cash provided by (used in) operating activities for fiscal 2022 was -$15.58M.
- INMED PHARMACEUTICALS INC. net cash provided by (used in) operating activities for fiscal 2021 was -$9.79M.
- INMED PHARMACEUTICALS INC. net cash provided by (used in) operating activities for fiscal 2020 was -$7.37M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month | Net Cash Provided by (Used in) Operating Activities 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | -$2.96M derived: S-4/A 12 month − S-4 9 month · filed 2026-09-09 | -$4.66M derived: sum of 2 quarters · filed 2026-09-09 | -$7.04M derived: sum of 3 quarters · filed 2026-09-09 | -$8.64M S-4/A · filed 2026-09-09 | |
| 2026-03-31 | -$1.70M derived: S-4 9 month − 10-Q 6 month · filed 2026-07-02 | -$4.07M derived: sum of 2 quarters · filed 2026-07-02 | -$5.68M S-4 · filed 2026-07-02 | -$7.79M derived: sum of 4 quarters · filed 2026-09-09 | |
| 2025-12-31 | -$2.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-11 | -$3.98M 10-Q · filed 2026-02-11 | -$6.09M derived: sum of 3 quarters · filed 2026-09-09 | -$7.75M derived: sum of 4 quarters · filed 2026-09-09 | |
| 2025-09-30 | -$1.61M 10-Q · filed 2025-11-06 | -$3.72M derived: sum of 2 quarters · filed 2026-09-09 | -$5.38M derived: sum of 3 quarters · filed 2026-09-09 | -$7.88M derived: sum of 4 quarters · filed 2026-09-09 | |
| 2025-06-30 | -$2.11M derived: S-4/A 12 month − S-4 9 month · filed 2026-09-09 | -$3.77M derived: sum of 2 quarters · filed 2026-09-09 | -$6.27M derived: sum of 3 quarters · filed 2026-09-09 | -$8.10M S-4/A · filed 2026-09-09 | -$7.77M 10-K · filed 2025-09-23 |
| 2025-03-31 | -$1.66M derived: S-4 9 month − 10-Q 6 month · filed 2026-07-02 | -$4.16M derived: sum of 2 quarters · filed 2026-07-02 | -$5.99M S-4 · filed 2026-07-02 | -$7.02M derived: sum of 4 quarters · filed 2026-07-02 | |
| 2024-12-31 | -$2.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-11 | -$4.33M 10-Q · filed 2026-02-11 | -$5.36M derived: sum of 3 quarters · filed 2026-07-02 | -$7.29M derived: sum of 4 quarters · filed 2026-07-02 | |
| 2024-09-30 | -$1.83M 10-Q · filed 2025-11-06 | -$2.86M derived: sum of 2 quarters · filed 2026-07-02 | -$4.79M derived: sum of 3 quarters · filed 2026-07-02 | -$6.64M derived: sum of 4 quarters · filed 2026-07-02 | |
| 2024-06-30 | -$1.03M derived: S-4 12 month − 10-Q 9 month · filed 2026-07-02 | -$2.96M derived: sum of 2 quarters · filed 2026-07-02 | -$4.81M derived: sum of 3 quarters · filed 2026-07-02 | -$6.99M S-4 · filed 2026-07-02 | |
| 2024-03-31 | -$1.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-12 | -$3.78M derived: sum of 2 quarters · filed 2025-05-12 | -$5.96M 10-Q · filed 2025-05-12 | -$6.61M derived: sum of 4 quarters · filed 2025-05-12 | |
| 2023-12-31 | -$1.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-02-12 | -$4.02M 10-Q · filed 2025-02-12 | -$4.68M derived: sum of 3 quarters · filed 2025-02-12 | -$6.34M derived: sum of 4 quarters · filed 2025-02-12 | |
| 2023-09-30 | -$2.17M 10-Q · filed 2024-11-14 | -$2.83M derived: sum of 2 quarters · filed 2024-11-14 | -$4.49M derived: sum of 3 quarters · filed 2024-11-14 | -$7.20M derived: sum of 4 quarters · filed 2024-11-14 | |
| 2023-06-30 | -$657.93K derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-30 | -$2.31M derived: sum of 2 quarters · filed 2024-09-30 | -$5.03M derived: sum of 3 quarters · filed 2024-09-30 | -$7.28M 10-K · filed 2024-09-30 | |
| 2023-03-31 | -$1.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-05-15 | -$4.37M derived: sum of 2 quarters · filed 2024-02-13 | -$6.63M 10-Q · filed 2023-05-15 | -$10.67M derived: sum of 4 quarters · filed 2024-02-13 | |
| 2022-12-31 | -$2.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-02-13 | -$4.97M 10-Q · filed 2024-02-13 | -$9.02M derived: sum of 3 quarters · filed 2024-02-13 | -$14.36M derived: sum of 4 quarters · filed 2024-02-13 | |
| 2022-09-30 | -$2.26M 10-Q · filed 2023-11-14 | -$6.30M derived: sum of 2 quarters · filed 2023-11-14 | -$11.65M derived: sum of 3 quarters · filed 2023-11-14 | -$15.19M derived: sum of 4 quarters · filed 2023-11-14 | |
| 2022-06-30 | -$4.05M derived: 10-K 12 month − 10-Q 9 month · filed 2023-09-29 | -$9.40M derived: sum of 2 quarters · filed 2023-09-29 | -$12.93M derived: sum of 3 quarters · filed 2023-09-29 | -$15.58M 10-K · filed 2023-09-29 | |
| 2022-03-31 | -$5.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-05-15 | -$8.88M derived: sum of 2 quarters · filed 2023-05-15 | -$11.54M 10-Q · filed 2023-05-15 | -$13.54M derived: sum of 4 quarters · filed 2023-05-15 | |
| 2021-12-31 | -$3.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-02-17 | -$6.19M 10-Q · filed 2023-02-17 | -$8.19M derived: sum of 3 quarters · filed 2023-02-17 | -$12.81M derived: sum of 4 quarters · filed 2023-02-17 | |
| 2021-09-30 | -$2.65M 10-Q · filed 2022-11-14 | -$4.66M derived: sum of 2 quarters · filed 2022-11-14 | -$9.27M derived: sum of 3 quarters · filed 2022-11-14 | -$11.07M derived: sum of 4 quarters · filed 2022-11-14 | |
| 2021-06-30 | -$2.01M derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-23 | -$6.62M derived: sum of 2 quarters · filed 2022-09-23 | -$8.42M derived: sum of 3 quarters · filed 2022-09-23 | -$9.79M 10-K · filed 2022-09-23 | |
| 2021-03-31 | -$4.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-05-13 | -$6.41M derived: sum of 2 quarters · filed 2022-05-13 | -$7.78M 10-Q · filed 2022-05-13 | -$9.18M derived: sum of 4 quarters · filed 2022-05-13 | |
| 2020-12-31 | -$1.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-02-14 | -$3.17M 10-Q · filed 2022-02-14 | -$4.57M derived: sum of 3 quarters · filed 2022-02-14 | -$6.09M derived: sum of 4 quarters · filed 2022-02-14 | |
| 2020-09-30 | -$1.37M 10-Q · filed 2021-11-10 | -$2.77M derived: sum of 2 quarters · filed 2021-11-10 | -$4.29M derived: sum of 3 quarters · filed 2021-11-10 | -$6.38M derived: sum of 4 quarters · filed 2021-11-10 | |
| 2020-06-30 | -$1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2021-09-24 | -$2.92M derived: sum of 2 quarters · filed 2021-09-24 | -$5.01M derived: sum of 3 quarters · filed 2021-09-24 | -$7.37M 10-K · filed 2021-09-24 | |
| 2020-03-31 | -$1.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-05-13 | -$3.61M derived: sum of 2 quarters · filed 2021-05-13 | -$5.98M 10-Q · filed 2021-05-13 | ||
| 2019-12-31 | -$2.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-02-11 | -$4.46M 10-Q · filed 2021-02-11 | |||
| 2019-09-30 | -$2.37M 10-Q · filed 2020-12-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |